Nymox reports NX-1207 Phase 2 treatment 'positive' results Nymox Pharmaceutical reported "positive" new study findings showing that the company's NX-1207 Phase 2 treatment for localized low-risk prostate cancer did not affect testosterone levels in treated men. Analysis of testosterone levels post-treatment for men treated with NX-1207 2.5 mg or 15 mg showed no statistically significant change as compared to control active surveillance patients. This data is consistent with the large body of existing data for men treated with NX-1207 showing a favorable sexual profile for the treatment. One of the major problems with current prostate treatments for localized prostate cancer is the relatively high incidence of reported sexual dysfunction post-treatment. In now 8 completed studies, NX-1207 treatment has shown to have no significant adverse effect post-treatment on sexual function or testosterone levels.For the NX03-0040 study, previously reported study results showed that patients with NX-1207 treatment had significantly less Gleason grade progression, lower average PSA levels, lower numbers of biopsy cores showing greater malignancy, and lower total volume of more malignant cancer compared to controls.